Enanta Pharmaceuticals | ENTA - Operating Profit


Enanta Pharmaceuticals reported $-23.54M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Amgen USD 4.61B 777M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD 700.4M 376.22M Jun/2026
Insmed USD -101.31M 98.97M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
Merck USD 840M 2.72B Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 667M 4.32B Jun/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026